EDACO, a derivative of myricetin, inhibits the differentiation of Gaoyou duck embryonic osteoclasts in vitro.

This study determined the effects of (E)-3-(2-(4-(3-(2,4-dimethoxyphenyl)acryloyl)phenoxy)ethoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one (EDACO) on the differentiation of Gaoyou duck embryonic osteoclasts cultured in vitro. Bone marrow mononuclear cells (BM-MNC) were collected from 23-day-old Gaoyou duck embryos and induced by macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL) in the presence of EDACO at different concentrations (i.e., 10, 20, 40, 80, and 160 µM). Tartrate-resistant acid phosphatase (TRAP) staining and resorption ability determination were conducted. Results suggested that EDACO suppressed the shaping of positive multinucleated cells and the number of TRAP-positive cells in the 20, 40, 80, 160 μM EDACO groups was significantly decreased (P<0.05, or P<0.01). Besides, the absorption activity of differentiated duck embryonic osteoclasts was significantly inhibited (P<0. 05) both in 80 and 160 μM EDACO groups. Overall, EDACO can inhibit the differentiation of BM-MNC into mature osteoclasts in duck embryos.